First treatment for AL Amyloidosis approved in US
Daratumumab has just been granted approval by the FDA for the treatment of AL Amyloidosis in the United States. Today marks a major milestone and an achievement that has been years in the making. Janssen applied for FDA approval for...
Remembering Janice Wiesman
The Amyloidosis Research Consortium extends our deepest, heartfelt condolences to the family and friends of Dr. Janice Wiesman. She was considered the world authority on the neurological ramifications of amyloidosis. (more…)
Amyloidosis Masterclass: The Art and Science of Managing Amyloidosis
The Amyloidosis Research Consortium (ARC) is excited to announce the first in a series of physician education “Masterclasses” to take place on January 10, 2020 in Dallas, TX. (more…)
FDA appoints Public Private Partnership Liaison to ARC
To focus on the challenges faced by AL amyloidosis, a particularly complex and multi-systemic disease, and bridge the gaps in drug discovery and development . (more…)
Patient Perspectives from the FDA Public Meeting: the Impact of Rare Diseases
I recently had the opportunity to attend this public meeting at the FDA to discuss the Patient Perspectives on the Impact of Rare Diseases. This meeting was held as opportunity to bring the voices of patients and caregivers to the...